FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008030967> ?p ?o ?g. }

• W3008030967 endingPage "145" @default.
• W3008030967 startingPage "135" @default.
• W3008030967 abstract "Abstract Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy, is a severe developmental and epileptic encephalopathy caused by loss-of-function mutations in one copy of SCN1A (haploinsufficiency), located on chromosome 2q24, with decreased function of Nav1.1 sodium channels in GABAergic inhibitory interneurons. Pharmacoresistant seizures in DS start in the infancy in the form of hemiclonic febrile status epilepticus. Later, other intractable seizure types develop including myoclonic seizures. Early normal development in infancy evolves into moderate to severe intellectual impairment, motor impairment, behavioral abnormalities, and later a characteristic crouching gait. Clobazam, valproate, levetiracetam, topiramate, zonisamide, ketogenic diet, and vagus nerve stimulation had been shown to be effective, but even with polytherapy, only 10% of patients get adequate seizure control. The author provides a narrative review of the current treatment paradigm as well as recent advances in the management of DS based on a comprehensive literature review (MEDLINE using PubMed and OvidSP vendors with appropriate keywords to incorporate recent evidence), personal practice, and experience. In recent years, the treatment paradigm of DS is changing with the approval of pharmaceutical-grade cannabidiol oil and stiripentol. Another novel antiepileptic drug (AED), fenfluramine, had also shown excellent efficacy in phase 3 studies of DS. However, these AEDs primarily control seizures without addressing the underlying pathogenesis and other important common comorbidities such as cognitive impairment, autistic behavior, neuropsychiatric abnormalities, and motor impairment including crouching gait. Several agents targeted for DS are in the developmental stage: TAK935, lorcaserin, clemizole, huperzine analog, ataluren, selective sodium channel modulators and activators, antisense oligonucleotide therapy, and adenoviral vector therapy. As DS is associated with a high risk of sudden unexpected death in epilepsy, seizure detection devices can be used in this population for testing and clinical validation of these devices." @default.
• W3008030967 created "2020-03-06" @default.
• W3008030967 creator A5062714811 @default.
• W3008030967 date "2020-02-20" @default.
• W3008030967 modified "2023-09-24" @default.
• W3008030967 title "Changing Landscape of Dravet Syndrome Management: An Overview" @default.
• W3008030967 cites W1568219566 @default.
• W3008030967 cites W1588443162 @default.
• W3008030967 cites W1689066679 @default.
• W3008030967 cites W1926532831 @default.
• W3008030967 cites W1986761885 @default.
• W3008030967 cites W1990156650 @default.
• W3008030967 cites W1992787503 @default.
• W3008030967 cites W1998851484 @default.
• W3008030967 cites W2000666285 @default.
• W3008030967 cites W2005107590 @default.
• W3008030967 cites W2036398344 @default.
• W3008030967 cites W2037693985 @default.
• W3008030967 cites W2040934129 @default.
• W3008030967 cites W2042948558 @default.
• W3008030967 cites W2048186906 @default.
• W3008030967 cites W2056828047 @default.
• W3008030967 cites W2057554220 @default.
• W3008030967 cites W2058764682 @default.
• W3008030967 cites W2059513413 @default.
• W3008030967 cites W2063641258 @default.
• W3008030967 cites W2063801230 @default.
• W3008030967 cites W2083064460 @default.
• W3008030967 cites W2083198897 @default.
• W3008030967 cites W2083980682 @default.
• W3008030967 cites W2101383744 @default.
• W3008030967 cites W2140968331 @default.
• W3008030967 cites W2153855789 @default.
• W3008030967 cites W2160485730 @default.
• W3008030967 cites W2216639980 @default.
• W3008030967 cites W2280631766 @default.
• W3008030967 cites W2353377670 @default.
• W3008030967 cites W238111488 @default.
• W3008030967 cites W2396520718 @default.
• W3008030967 cites W2398625550 @default.
• W3008030967 cites W2399319535 @default.
• W3008030967 cites W2402833179 @default.
• W3008030967 cites W2506966996 @default.
• W3008030967 cites W2530807081 @default.
• W3008030967 cites W2539458271 @default.
• W3008030967 cites W2544534185 @default.
• W3008030967 cites W2568121822 @default.
• W3008030967 cites W2575422812 @default.
• W3008030967 cites W2576396354 @default.
• W3008030967 cites W2583598024 @default.
• W3008030967 cites W2606268204 @default.
• W3008030967 cites W2620218661 @default.
• W3008030967 cites W2625767512 @default.
• W3008030967 cites W2763605737 @default.
• W3008030967 cites W2767723993 @default.
• W3008030967 cites W2789986119 @default.
• W3008030967 cites W2800669514 @default.
• W3008030967 cites W2811424796 @default.
• W3008030967 cites W2888643586 @default.
• W3008030967 cites W2905603477 @default.
• W3008030967 cites W2910402004 @default.
• W3008030967 cites W2923767020 @default.
• W3008030967 cites W2961503558 @default.
• W3008030967 cites W2962402170 @default.
• W3008030967 cites W65245889 @default.
• W3008030967 doi "https://doi.org/10.1055/s-0040-1701694" @default.
• W3008030967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32079034" @default.
• W3008030967 hasPublicationYear "2020" @default.
• W3008030967 type Work @default.
• W3008030967 sameAs 3008030967 @default.
• W3008030967 citedByCount "23" @default.
• W3008030967 countsByYear W30080309672021 @default.
• W3008030967 countsByYear W30080309672022 @default.
• W3008030967 countsByYear W30080309672023 @default.
• W3008030967 crossrefType "journal-article" @default.
• W3008030967 hasAuthorship W3008030967A5062714811 @default.
• W3008030967 hasConcept C118552586 @default.
• W3008030967 hasConcept C15744967 @default.
• W3008030967 hasConcept C169760540 @default.
• W3008030967 hasConcept C187212893 @default.
• W3008030967 hasConcept C2775859823 @default.
• W3008030967 hasConcept C2777138316 @default.
• W3008030967 hasConcept C2777332695 @default.
• W3008030967 hasConcept C2777341932 @default.
• W3008030967 hasConcept C2777683783 @default.
• W3008030967 hasConcept C2777907850 @default.
• W3008030967 hasConcept C2778186239 @default.
• W3008030967 hasConcept C2778587478 @default.
• W3008030967 hasConcept C2780623815 @default.
• W3008030967 hasConcept C71924100 @default.
• W3008030967 hasConceptScore W3008030967C118552586 @default.
• W3008030967 hasConceptScore W3008030967C15744967 @default.
• W3008030967 hasConceptScore W3008030967C169760540 @default.
• W3008030967 hasConceptScore W3008030967C187212893 @default.
• W3008030967 hasConceptScore W3008030967C2775859823 @default.
• W3008030967 hasConceptScore W3008030967C2777138316 @default.
• W3008030967 hasConceptScore W3008030967C2777332695 @default.
• W3008030967 hasConceptScore W3008030967C2777341932 @default.

• next